Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Transplantation and Cellular Therapy|June 9, 2026
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regressionAinsley Ryan Yan Bin Lee, Hon Jen Wong, Chi Ching Lim, et al.JCO Clinical Cancer Informatics|February 12, 2026
Prompt Engineering for Eastern Cooperative Oncology Group Status Extraction: Comparing Large Language Model TechniquesMeenakshi Dubey, Kok Joon Chong, Yuba Raj Pun, et al.Plos One|July 14, 2011
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationDouglas W McMillin, Jake Delmore, Joseph Negri, et al.Leukemia & Lymphoma|December 16, 2025
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744)Melinda S Y Tan, Chandramouli Nagarajan, Melissa Ooi, et al.Singapore Medical Journal|September 10, 2016
The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myelomaSanjay de Mel, Yunxin Chen, Sathish Kumar Gopalakrishnan, et al.JCO Oncology Practice|October 16, 2023
Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent LymphomaChia Jie Tan, Melinda Si Yun Tan, Chandramouli Nagarajan, et al.Cancers|July 27, 2022
Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and AzacitidineShin Yeu Ong, Melinda Tan Si Yun, Nurul Aidah Abdul Halim, et al.Cancer Research|July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.Current Hematologic Malignancy Reports|July 3, 2023
Response-Adapted Therapy for Newly Diagnosed Multiple MyelomaWinnie Z Y Teo, Ian Y E Ong, Jason W Y Tong, et al.Pageof 4